BioSpace News Archive

Smith+Nephew, the global medical technology business, announces its newly launched OR3O Dual Mobility System for total hip arthroplasty has received encouraging results from early surgeon experience.

Detroit-based Redcliffe Medical has launched a breakthrough transparent face mask with state of the art N99+ HEPA-Carbon filtration, powered by optional UV self-sterilization and active ventilation.

Duality Technologies, a leading provider of Privacy-Enhancing Technologies (PETs), announced today the publication of an article in PNAS (Proceedings of the National Academy of Sciences of the United States of America), on Secure large-scale genome-wide association studies using homomorphic encryption.

Windtree Therapeutics, Inc. (OTCQB: WINTD), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2020 and provided key business updates.

- Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting - [14-May-2020] SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid

Target Selector™ molecular assay kits are research-use-only (RUO) and offer superior sensitivity compared to NGS-based biomarker analysis for the detection of key actionable oncogene mutations [14-May-2020] SAN DIEGO , May 14, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians wit

Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing. Even at low concentrations of both drugs significant reduction in viral production occurs. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (Nasdaq: BSGM ) today

CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter® FLEX Analysis System, Veracyte’s diagnostic platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2020051400

Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine.

Envafolimab Demonstrated a 30% Confirmed Objective Response Rate (ORR) by RECIST by Independent Central Review in Patients with Advanced Refractory MSI-H/dMMR Colorectal and Gastric Cancer ORR and Other Data will be Updated at ASCO TRACON Expects to Initiate its Pivotal ENVASARC Trial of Envafolimab in Sarcoma in Second Half of 2020 SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development